קסלודה 150 מ"ג Israel - ebraică - Ministry of Health

קסלודה 150 מ"ג

roche pharmaceuticals (israel) ltd - capecitabine 150 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

קסלודה 500 מ"ג Israel - ebraică - Ministry of Health

קסלודה 500 מ"ג

roche pharmaceuticals (israel) ltd - capecitabine 500 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

דקוג'ן Israel - ebraică - Ministry of Health

דקוג'ן

j-c health care ltd - decitabine - אבקה להכנת תמיסה מרוכזת לעירוי - decitabine 50 mg/vial - decitabine - decitabine - - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including prevviously treated and untreated, de novo and secondary mds of all french-american- british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia ) and intermediate- 1, intermediate- 2, and high-risk international prognostic scoring system groups.- dacogen is indicated for the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

נבלבין 30 מג Israel - ebraică - Ministry of Health

נבלבין 30 מג

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 30 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

פקליאבניר Israel - ebraică - Ministry of Health

פקליאבניר

bioavenir ltd, israel - paclitaxel - תמיסה להזרקה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer: paclitaxel, associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. keposi's sarcoma: paclitaxel is indicated in the second- line treatment of aid's related kaposi's sarcoma.paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.for the treatment of advanced gastric carcinoma.

אבטקסל 6 מגמל Israel - ebraică - Ministry of Health

אבטקסל 6 מגמל

novartis israel ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically containdicated. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. advanced non small cell lung cancer: paclitaxel associated with cisplatinum is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis's sarcoma: paclitaxel is indicated in the second-line treatment of aids related kaposi's sarcoma. for the treatment of advanced gastric carcinoma.

פקליטקסל טבע  Israel - ebraică - Ministry of Health

פקליטקסל טבע

teva israel ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

פקליטקסל טבע  Israel - ebraică - Ministry of Health

פקליטקסל טבע

salomon,levin & elstein ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

רמוואב Israel - ebraică - Ministry of Health

רמוואב

neopharm scientific ltd - catumaxomab 100 mcg/ml - concentrate for solution for infusion - catumaxomab - intraperitoneal treatment of malignant ascites in patients with epcam-positive carcinomas where standard therapy is not available or no longer feasible.

פמרה Israel - ebraică - Ministry of Health

פמרה

novartis israel ltd - letrozole - טבליות מצופות פילם - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.